Sponsored Links


Displaying her2 PowerPoint Presentations

Allred IHC Score - Projects In Knowledge PPT

Presentation Summary : Allred Immunohistochemistry Score Proportion ... Odds Ratio for Treatment Failure According to Tumor HER2 Status in Patients Treated with Endocrine Agents ...

Source : http://www.projectsinknowledge.com/Activity/slides/1808.01.ppt

Historical overview of FDA regulation of digital pathology ... PPT

Presentation Summary : Historical overview of FDA regulation of digital pathology imaging applications: the safety and effectiveness issues Tremel A. Faison, MS, RAC, SCT(ASCP)

Source : http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/HematologyandPathologyDevicesPanel/UCM201450.ppt

Slide 1 PPT

Presentation Summary : Introduction. The 2007 guideline created a diagnostic algorithm for HER2 testing by acceptable testing methods of immunohistochemisty (IHC) and fluorescence in situ ...

Source : http://www.cap.org/apps/docs/committees/immunohistochemistry/her2_presentation.pptx

Treatment of HER2-Positive Gastroesophageal Carcinoma PPT

Presentation Summary : Treatment of HER2-Positive Gastroesophageal Carcinoma Manish A. Shah, MD Director, Gastrointestinal Oncology Weill Cornell Medical College NewYork-Presbyterian Hospital

Source : http://s3.amazonaws.com/GECarcinoma/CCO_GE_Carcinoma_Shah_Slides.ppt

stke.sciencemag.org PPT

Presentation Summary : ... (HER2+), and TN cancers. Data are means ± SEM from three cases per subtype relative to the background (tumor cells cross without the presence of macrophages).

Source : http://stke.sciencemag.org/highwire/powerpoint/6069804%3Fppt_destination%3Dcontent/7/353/ra112.full

biotherapy.vc.ons.org PPT

Presentation Summary : biotherapy.vc.ons.org

Source : http://biotherapy.vc.ons.org/file_depot/0-10000000/0-10000/3359/folder/108851/what+new+in+her+2+posted.pptx

Novel Her-2 Targeted agents PPT

Presentation Summary : ESMO 2010 HER2-positive, locally advanced or metastatic BC; previously received trastuzumab-based therapy Lapatinib (1250 mg/day) (Days 1–21) + Capecitabine ...

Source : http://cdn2.imng.com/fileadmin/images/onc/slideshows/NovelHer-2_targeted_agents.2.25.11.ppt

Sponsored Links
If you find powerpoint presentation a copyright It is important to understand and respect the copyright rules of the author.
Please do not download if you find presentation copyright.
If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com